

Julia G Prado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4999979/publications.pdf>

Version: 2024-02-01

65
papers

4,872
citations

218592

26
h-index

143943

57
g-index

73
all docs

73
docs citations

73
times ranked

4707
citing authors

#	ARTICLE	IF	CITATIONS
1	Viral and Cellular Factors Leading to the Loss of CD4 Homeostasis in HIV-1 Viremic Nonprogressors. <i>Journal of Virology</i> , 2022, 96, JV0149921.	1.5	0
2	Immunoescape of HIV-1 in Env-EL9 CD8 ⁺ T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control. <i>Retrovirology</i> , 2022, 19, 6.	0.9	3
3	Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
4	Neurocognitive Profile of the Post-COVID Condition in Adults in Catalonia—A Mixed Method Prospective Cohort and Nested Case–Control Study: Study Protocol. <i>Vaccines</i> , 2022, 10, 849.	2.1	1
5	Antibody cooperative adsorption onto AuNPs and its exploitation to force natural killer cells to kill HIV-infected T cells. <i>Nano Today</i> , 2021, 36, 101056.	6.2	7
6	VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies. <i>MBio</i> , 2021, 12, e0056021.	1.8	9
7	Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab329.	0.4	7
8	SARS-CoV-2 Consensus-Sequence and Matching Overlapping Peptides Design for COVID19 Immune Studies and Vaccine Development. <i>Vaccines</i> , 2020, 8, 444.	2.1	11
9	HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2535-2546.	1.3	7
10	Editorial: Immune Surveillance of the HIV Reservoir: Mechanisms, Therapeutic Targeting and New Avenues for HIV Cure. <i>Frontiers in Immunology</i> , 2020, 11, 70.	2.2	2
11	Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection. <i>JAMA Oncology</i> , 2020, 6, 1063.	3.4	70
12	Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infection. <i>Nature Communications</i> , 2020, 11, 1767.	5.8	15
13	Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa. <i>Nature Communications</i> , 2019, 10, 4739.	5.8	79
14	Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8 ⁺ T Cells Limit the Killing of HIV-1 Reactivated Cells. <i>Frontiers in Immunology</i> , 2019, 9, 3162.	2.2	17
15	Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2019, 133, 2291-2304.	0.6	87
16	Enhancement of Antiviral CD8 ⁺ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 2089.	1.0	20
17	Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses. <i>Journal of Virology</i> , 2018, 92, .	1.5	7
18	Differential Immunodominance Hierarchy of CD8 ⁺ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. <i>Journal of Virology</i> , 2018, 92, .	1.5	14

#	ARTICLE	IF	CITATIONS
19	Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection. <i>Journal of Virology</i> , 2018, 92, .	1.5	58
20	Restriction Factors: From Intrinsic Viral Restriction to Shaping Cellular Immunity Against HIV-1. <i>Frontiers in Immunology</i> , 2018, 9, 2876.	2.2	141
21	CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir. <i>Nature Communications</i> , 2018, 9, 2739.	5.8	61
22	Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors. <i>Scientific Reports</i> , 2017, 7, 3717.	1.6	13
23	CD8 ⁺ T Cell Breadth and <i>Ex Vivo</i> Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles. <i>Journal of Virology</i> , 2016, 90, 6818-6831.	1.5	27
24	Nonhuman TRIM5 Variants Enhance Recognition of HIV-1-Infected Cells by CD8 ⁺ T Cells. <i>Journal of Virology</i> , 2016, 90, 8552-8562.	1.5	11
25	Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation. <i>Journal of Virology</i> , 2016, 90, 6148-6158.	1.5	50
26	Discordant Impact of HLA on Viral Replicative Capacity and Disease Progression in Pediatric and Adult HIV Infection. <i>PLoS Pathogens</i> , 2015, 11, e1004954.	2.1	64
27	SAMHD1 Limits HIV-1 Antigen Presentation by Monocyte-Derived Dendritic Cells. <i>Journal of Virology</i> , 2015, 89, 6994-7006.	1.5	23
28	TRIM5 α Improves CD8 ⁺ T-cell Antiviral Activity and Synergize Intrinsic Restriction and Adaptive Immunity in HIV-1 Infected Cells. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A177-A178.	0.5	0
29	Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression. <i>Aids</i> , 2014, 28, 1261-1272.	1.0	18
30	Differential Escape Patterns within the Dominant HLA-B*57:03-Restricted HIV Gag Epitope Reflect Distinct Clade-Specific Functional Constraints. <i>Journal of Virology</i> , 2014, 88, 4668-4678.	1.5	17
31	Reduction in Breadth and Not Polyfunctionality or Proliferative Capacity of CD8 ⁺ T Cells Is Associated with Loss of Virologic HIV Control. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A75-A75.	0.5	0
32	Early Antigen Presentation of Protective HIV-1 KF11Gag and KK10Gag Epitopes from Incoming Viral Particles Facilitates Rapid Recognition of Infected Cells by Specific CD8 ⁺ T Cells. <i>Journal of Virology</i> , 2013, 87, 2628-2638.	1.5	40
33	Sialyllactose in Viral Membrane Gangliosides Is a Novel Molecular Recognition Pattern for Mature Dendritic Cell Capture of HIV-1. <i>PLoS Biology</i> , 2012, 10, e1001315.	2.6	78
34	A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 32-38.	1.3	7
35	Novel Two-Round Phenotypic Assay for Protease Inhibitor Susceptibility Testing of Recombinant and Primary HIV-1 Isolates. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3909-3916.	1.8	6
36	HIV-1 Capture and Antigen Presentation by Dendritic Cells: Enhanced Viral Capture Does Not Correlate with Better T Cell Activation. <i>Journal of Immunology</i> , 2012, 188, 6036-6045.	0.4	21

#	ARTICLE	IF	CITATIONS
37	Virus Immune Evasion: New Mechanism and Implications in Disease Outcome. <i>Advances in Virology</i> , 2012, 2012, 1-1.	0.5	3
38	Inâ€“Depth Characterization of Viral Isolates from Plasma and Cells Compared with Plasma Circulating Quasispecies in Early HIV-1 Infection. <i>PLoS ONE</i> , 2012, 7, e32714.	1.1	14
39	Immune Correlates of HIV Control. <i>Current Medicinal Chemistry</i> , 2011, 18, 3963-3970.	1.2	4
40	Dynamic Imaging of Cellâ€“Free and Cellâ€“Associated Viral Capture in Mature Dendritic Cells. <i>Traffic</i> , 2011, 12, 1702-1713.	1.3	32
41	HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. <i>Aids</i> , 2010, 24, 491-502.	1.0	152
42	Replicative Capacity of Human Immunodeficiency Virus Type 1 Transmitted from Mother to Child Is Associated with Pediatric Disease Progression Rate. <i>Journal of Virology</i> , 2010, 84, 492-502.	1.5	33
43	Efficacious Early Antiviral Activity of HIV Gag- and Pol-Specific HLA-B*2705-Restricted CD8 + T Cells. <i>Journal of Virology</i> , 2010, 84, 10543-10557.	1.5	84
44	HLA-Cw*03-Restricted CD8⁺ T-Cell Responses Targeting the HIV-1 Gag Major Homology Region Drive Virus Immune Escape and Fitness Constraints Compensated for by Intracodon Variation. <i>Journal of Virology</i> , 2010, 84, 11279-11288.	1.5	25
45	Impact of HLA in Mother and Child on Disease Progression of Pediatric Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2009, 83, 10234-10244.	1.5	50
46	Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703â€“positive individuals and their transmission recipients. <i>Journal of Experimental Medicine</i> , 2009, 206, 909-921.	4.2	165
47	Chapter 1 HLAâ€“Mediated Control of HIV and HIV Adaptation to HLA. <i>Advances in Parasitology</i> , 2009, 68, 1-20.	1.4	7
48	Functional Consequences of Human Immunodeficiency Virus Escape from an HLA-B*13-Restricted CD8+ T-Cell Epitope in p1 Gag Protein. <i>Journal of Virology</i> , 2009, 83, 1018-1025.	1.5	54
49	Adaptation of HIV-1 to human leukocyte antigen class I. <i>Nature</i> , 2009, 458, 641-645.	13.7	408
50	P07-07. Non-progressive paediatric HIV infection is associated with virus attenuation and increase in CD8+ specific T cell responses over time. <i>Retrovirology</i> , 2009, 6, .	0.9	0
51	OA031-01. HIV-1 infection is characterized by early loss of CD161+ Th17 cells and gradual decline in regulatory T cells. <i>Retrovirology</i> , 2009, 6, .	0.9	0
52	P09-18. Cw*0303/0304 HIV specific CTL response toward GagYL9 select for HIV escape variants with low fitness that is compensated by intra-codon variation. <i>Retrovirology</i> , 2009, 6, P131.	0.9	0
53	Compensatory Mutation Partially Restores Fitness and Delays Reversion of Escape Mutation within the Immunodominant HLA-B*5703-Restricted Gag Epitope in Chronic Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2008, 82, 3161-3161.	1.5	0
54	Relative Fitness and Replication Capacity of a Multinucleoside Analogue-Resistant Clinical Human Immunodeficiency Virus Type 1 Isolate with a Deletion of Codon 69 in the Reverse Transcriptase Coding Region. <i>Journal of Virology</i> , 2007, 81, 4713-4721.	1.5	23

#	ARTICLE	IF	CITATIONS
55	Compensatory Mutation Partially Restores Fitness and Delays Reversion of Escape Mutation within the Immunodominant HLA-B*5703-Restricted Gag Epitope in Chronic Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2007, 81, 8346-8351.	1.5	197
56	CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. <i>Nature Medicine</i> , 2007, 13, 46-53.	15.2	910
57	Fitness Cost of Escape Mutations in p24 Gag in Association with Control of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2006, 80, 3617-3623.	1.5	408
58	HIV Type 1 Fitness Evolution in Antiretroviral-Experienced Patients with Sustained CD4+ T Cell Counts but Persistent Virologic Failure. <i>Clinical Infectious Diseases</i> , 2005, 41, 729-737.	2.9	22
59	Immune Selection for Altered Antigen Processing Leads to Cytotoxic T Lymphocyte Escape in Chronic HIV-1 Infection. <i>Journal of Experimental Medicine</i> , 2004, 199, 905-915.	4.2	266
60	Lack of Longitudinal Inpatient Correlation between p24 Antigenemia and Levels of Human Immunodeficiency Virus (HIV) Type 1 RNA in Patients with Chronic HIV Infection during Structured Treatment Interruptions. <i>Journal of Clinical Microbiology</i> , 2004, 42, 1620-1625.	1.8	26
61	HIV evolution: CTL escape mutation and reversion after transmission. <i>Nature Medicine</i> , 2004, 10, 282-289.	15.2	769
62	Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. <i>Virology</i> , 2004, 326, 103-112.	1.1	35
63	Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. <i>Aids</i> , 2002, 16, 895-899.	1.0	85
64	Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. <i>Aids</i> , 2002, 16, 1009-1017.	1.0	92
65	Inmunoterapias del cáncer: ¿el Santo Grial para la curación del VIH-1?. <i>Scientific Medical Data</i> , 0, , .	0.0	0